Swedish Healthtech Company 1928 Pushing Forward
In these new and challenging times many businesses are being hit hard by the pandemic. Companies are being forced to lay off personnel, slow down business and even shut down. Swedish Healthtech company 1928 are taking the opposite approach.
"The problem with Hospital Acquired Infections will not disappear. On the contrary, it may increase due to the Covid-19 pandemic. Patients are now overwhelming the ICUs globally where antibiotic resistant bacteria can be found in 25% of the cases under normal circumstances. Many of the Covid-19 patients may also suffer from secondary bacterial infections. We are committed to push through this challenge with self-confidence, a strong team and a great sense of urgency. Our continued strategy is to expand our business, recruit more people and to continue developing our service platform for Impact Infection Control", says 1928 CEO and co-founder, Dr. Kristina Lagerstedt.
Impact Infection Control
1928 is a full service analytics platform providing an effective solution for infection control. The data and reports create a foundation for precise analysis, fast response, more efficient use of resources, and increased chances for successful patient outcomes.
The 1928 software platform contains well-validated and specially adapted algorithms that processes the raw data file from the sequencing machine. By optimizing data handling processes in the cloud, the calculations are always efficient and fast due to optimized workflows and use of distributed systems. The processed data is matched to manually curated databases of genetic markers (genes and mutations) coding for antibiotic resistance or virulence factors.
The database entries are collected from peer reviewed scientific journals and comprise clinically relevant markers that are carefully selected and manually curated. The result is delivered on the platform in an informative format and can also be exported.
About the company
1928 was founded by four scientists and entrepreneurs within tech and healthcare to contribute in the combat against one of the greatest threats facing humanity – antibiotic resistance.
Since the foundation of the company in 2014, the company has commercialized Professor Erik Kristiansson’s research at Chalmers University of technology, Sweden, into a DNA analytics platform for healthcare providers to effectively track and minimize spread of superbugs globally. Dr. Kristina Lagerstedt and Dr. Susanne Staaf, with medical and big-pharma backgrounds, have operated 1928 together from day one and built the team of software developers, bioinformaticians, microbiologists and quality engineers of whom together have built the 1928 analysis platform for infection control.
The 1928 Chairman of the Board – tech and medtech serial entrepreneur Olof Sköld have guided the team based on his wide experiences and a clear vision.
Kristina Lagerstedt adds; "The work to improve healthcare quality globally cannot wait – not on our watch".